---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-003908"
form_type: "8-K"
ticker: null
cik: "0001900520"
company_name: "Lomond Therapeutics Holdings, Inc."
filed_at: "2026-01-13T23:59:59+00:00"
generated_at: "2026-05-16T10:43:12.786304+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lomond invests $9M in Idwal Therapeutics for Series A preferred units; option for $2M additional

## Summary
- Lomond purchased 3.1M Series A Preferred Units of Idwal at $2.90/unit for ~$9.0M; closing occurred Jan 8, 2026.
- Idwal formed with MALT-1 program assets from Tegid Therapeutics; total gross proceeds ~$47M from all investors.
- Lomond has option to invest additional ~$2.0M on same terms.
- Initial managers of Idwal are Lomond's directors: Iain Dukes, Nikolay Savchuk, Carl Gordon, Eddie Wang Rodriguez.

## SEC filing metadata
- accession: 0001213900-26-003908
- form_type: 8-K
- cik: 0001900520
- company_name: Lomond Therapeutics Holdings, Inc.
- filed_at: 2026-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1900520/000121390026003908/0001213900-26-003908-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1900520/000121390026003908/ea0272638-8k_lomond.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-003908
- JSON: https://secwatch.observer/filing/0001213900-26-003908.json
- Plain text: https://secwatch.observer/filing/0001213900-26-003908.txt

## Key facts
- Material Agreements
  Lomond Therapeutics Holdings, Inc. entered into Series A Preferred Unit Purchase Agreement with Idwal Therapeutics, LLC valued at approximately $9.0 million (effective 2026-01-08).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Idwal Therapeutics, LLC
  - Value: approximately $9.0 million
  - Effective: 2026-01-08
  source text: On January 8, 2026, Lomond Therapeutics Holdings, Inc. (the “Company”) entered into a Series A Preferred Unit Purchase Agreement (the “Purchase Agreement”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1900520/000121390026003908/0001213900-26-003908-index.htm
- Material Agreements
  Lomond Therapeutics Holdings, Inc. entered into Amended and Restated Limited Liability Company Agreement with Idwal Therapeutics, LLC (effective 2026-01-08).
  - Action: entry
  - Counterparty: Idwal Therapeutics, LLC
  - Effective: 2026-01-08
  source text: greement”) and related Amended and Restated Limited Liability Company Agreement (the “A&R LLC Agreement”) as an investor in Idwal Therapeutics, LLC (“Idwal”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1900520/000121390026003908/0001213900-26-003908-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.